Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1783 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 0.58 |
| drug1570 | Fondaparinux Wiki | 0.58 |
| drug1541 | Five-days oseltamivir Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2271 | Macrolide administered for 3-5 days Wiki | 0.58 |
| drug1544 | Fixed-duration Hydrocortisone Wiki | 0.58 |
| drug1397 | Enoxaparin 1 mg/kg Wiki | 0.58 |
| drug3952 | Ten-days oseltamivir Wiki | 0.58 |
| drug3056 | Prasugrel Wiki | 0.58 |
| drug3125 | Protocolised mechanical ventilation strategy Wiki | 0.58 |
| drug4019 | Tirofiban Injection Wiki | 0.58 |
| drug271 | Amoxicillin-clavulanate Wiki | 0.58 |
| drug1968 | Interferon-β1a Wiki | 0.58 |
| drug861 | Ceftaroline Wiki | 0.58 |
| drug4145 | Unfractionated Heparin IV Wiki | 0.58 |
| drug196 | Acetylsalicylic acid Wiki | 0.58 |
| drug4147 | Unfractionated heparin SC Wiki | 0.58 |
| drug4015 | Ticagrelor Wiki | 0.58 |
| drug2913 | Piperacillin-tazobactam Wiki | 0.58 |
| drug2272 | Macrolide administered for up to 14 days Wiki | 0.58 |
| drug2697 | Online Survey about Dietary and Lifestyle Habits Wiki | 0.58 |
| drug2440 | Moxifloxacin or Levofloxacin Wiki | 0.58 |
| drug3615 | Shock-dependent hydrocortisone Wiki | 0.58 |
| drug862 | Ceftriaxone Wiki | 0.58 |
| drug1545 | Fixed-duration higher dose Hydrocortisone Wiki | 0.58 |
| drug1415 | Eritoran Wiki | 0.58 |
| drug1398 | Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki | 0.41 |
| drug3628 | Simvastatin Wiki | 0.41 |
| drug3989 | Therapeutic anticoagulation Wiki | 0.41 |
| drug340 | Apremilast Wiki | 0.33 |
| drug356 | Aspirin Wiki | 0.29 |
| drug3532 | Sarilumab Wiki | 0.26 |
| drug274 | Anakinra Wiki | 0.19 |
| drug2174 | Lopinavir/ritonavir Wiki | 0.18 |
| drug4249 | Vitamin C Wiki | 0.15 |
| drug1060 | Convalescent plasma Wiki | 0.12 |
| drug4025 | Tocilizumab Wiki | 0.09 |
| drug1775 | Hydroxychloroquine Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016769 | Embolism and Thrombosis NIH | 0.29 |
| D013927 | Thrombosis NIH | 0.23 |
| D054556 | Venous Thromboembolism NIH | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001907 | Thromboembolism HPO | 0.25 |
| HP:0002090 | Pneumonia HPO | 0.06 |
Navigate: Correlations HPO
There are 3 clinical trials
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and not receiving organ support in ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital dischargeThis is a compassionate use, proof of concept, phase IIb, prospective, interventional, pilot study in which the investigators will evaluate the effects of compassionate-use treatment with IV tirofiban 25 mcg/kg, associated with acetylsalicylic acid IV, clopidogrel PO and fondaparinux 2.5 mg s/c, in patients affected by severe respiratory failure in Covid-19 associated pneumonia who underwent treatment with continuous positive airway pressure (CPAP).
Description: Change in ratio between partial pressure of oxygen in arterial blood, measured by means of arterial blood gas analysis, and inspired oxygen fraction at baseline and after study treatment
Measure: P/F ratio Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Change in partial pressure of oxygen in arterial blood, measured by means of arterial blood gas analysis, at baseline and after study treatment
Measure: PaO2 difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Change in alveolar-arterial gradient of oxygen at baseline and after study treatment. Arterial alveolar gradient will be calculated using the following parameters derived from arterial blood gas analysis: partial pressure of oxygen in arterial blood and partial pressure of carbon dioxide in arterial blood.
Measure: A-a O2 difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Number of days on continuous positive end expiratory pressure (CPAP)
Measure: CPAP duration Time: From the first day of study drugs administration (T0) until day 7 post study drugs administrationDescription: Difference in intensity of the respiratory support (non invasive mechanical ventilation, CPAP, high flow nasal cannula (HFNC), Venturi Mask, nasal cannula, from higher to lower intensity, respectively) employed at baseline and at 72 and 168 hours after study treatment initiation
Measure: In-hospital change in intensity of the respiratory support Time: At baseline and 72 and 168 hours after treatment initiationDescription: Difference in partial pressure of carbon dioxide in arterial blood, measured by means of arterial blood gas analysis, at baseline and after study treatment
Measure: PaCO2 difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Difference in concentration of bicarbonate in arterial blood, measured by means of arterial blood gas analysis, at baseline and after study treatment
Measure: HCO3- difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Difference in concentration of lactate in arterial blood, measured by means of arterial blood gas analysis, at baseline and after study treatment
Measure: Lactate difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Difference in hemoglobin concentration in blood samples, measured by means of blood chemistry test, at baseline and after study treatment.
Measure: Hb difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Difference in platelet concentration in blood samples, measured by means of blood chemistry test, at baseline and after study treatment.
Measure: Plt difference Time: At baseline and 24, 48 and 168 hours after treatment initiationDescription: Any major or minor adverse effect occuring during and after the administration of the study drug (e.g. bleeding)
Measure: Adverse effects Time: From the first day of study drugs administration until day 30 post study drugs administrationThis is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT
Measure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierDescription: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia
Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports